Pharmaceutical Sector - President Trump announced plans to reduce the price of Ozempic, a popular weight-loss and diabetes drug, to $150 per month from around $1,000, causing significant market reactions [2][3] - Shares of pharmaceutical companies like Eli Lilly and Novo Nordisk experienced immediate declines, with Novo Nordisk's American depositary receipts dropping by as much as 4.7% and Eli Lilly's shares falling by 5.3% [3] - Analysts provided mixed interpretations, with JPMorgan suggesting Trump's comments were expected, while BMO Capital Markets dismissed the situation as "aggressive posturing" [4] Market Reactions - Following Trump's tariff threat on Chinese imports, the Dow Jones Industrial Average fell by 1.9%, the S&P 500 dropped 2.7%, and the NASDAQ Composite decreased by 3.6%, resulting in a loss of $770 billion in market value for technology companies [6] - The market rebounded quickly after Trump adopted a more conciliatory tone, with the Dow gaining 574.91 points (+1.26%) and the NASDAQ climbing about 1.5% [8] - Analysts noted that the 100% tariff threat was likely more political theater than a real policy, with expectations of a trade truce [9] Geopolitical Developments - Trump's announcement to cut U.S. aid to Colombia did not result in significant market reactions, indicating that geopolitical issues may not impact markets as strongly as trade or pharmaceutical pricing [10] - The role of Truth Social in disseminating market-moving news was highlighted, with Digital World Acquisition Corp. experiencing volatility linked to Trump's posts [11] Overall Market Sentiment - The week illustrated the unpredictability of market reactions to Trump's statements, with rapid shifts in sentiment observed [12][13] - Investors appear to have developed resilience to volatility, swinging between panic and relief based on presidential pronouncements [12]